Last
Update:
September 09, 2007
Documents identified with this icon are in Portable Document Format (PDF)
and require the
Adobe
Acrobat Reader
4th IAS Conference on HIV Pathogenesis,
Treatment
and Prevention |
|
XVI
International AIDS Conference
|
Long
- term efficacy, safety, and tolerability of indinavir-based therapy in
nucleoside experienced
HIV-1-infected patients in a resource limited setting: 272 weeks follow up of
HIV-NAT 005 study
Avihingsanon A., Kerr S., Boyd M.,
et al
Abstract
Long
term durability of boosted indinavir and efavirenz in patients with
combination nucleoside analogue
failure in a resource constrained setting: 4- year follow-up of HIV-NAT 009
Avihingsanon A., Boyd M., Pornprasit P., et al
Abstract
J
Marquie-Beck, R Ellis, M Buzzell, et al
Abstract
-
The renal safety of long-term indinavir (IDV) therapy in subjects in ACTG
372A.
Gerber JG, Bassett R, Morse GD, Hammer SM
Abstract
-
Is
combination indinavir (400 mg bid) plus boosting dose of ritonavir (100 mg
bid) safe
enough: Belgrade study population?
Dragovic G., Jevtovic D.
Abstract
-
Biological characterization of HIV-1 subtype C protease carrying indinavir
drug resistance
mutations
Gonzalez O. L.M.F., Santana Aguiar R., Alfonzo A., et al
Abstract
-
The
renal safety of long-term indinavir (IDV) therapy in subjects in ACTG 372A.
Gerber J.G., Bassett R., Morse G.D., Hammer S.M.
Abstract
-
A
boosted protease inhibitors (Pis) strategy with Ritonavir (RTV) 100 mg
/Indinavir (IDV)
400 mg in HIV-1 infected patients in Mali (Bamako): The NOGOMA Study .
Cisse M., Canestri A., Marcelin A.-G., et al
Abstract
-
Good
renal tolerance of indinavir in adults with high indinavir plasma
concentration
in Abidjan
Danel C., Moh R., Peytavin G., Sorho S., et al
Abstract
-
Plasma spots on filter paper for the determination of indinavir (IDV)
concentrations in
HIV-infected African patients.
Boukobza S., Cisse M., Marcelin A., et al
Abstract
|
Indinavir Conference Citations |
|
4th
IAS Conference
Conference
Archives